OASIS: Rapid and deep responses to apalutamide plus ADT significantly improved survival in patients with mHSPC treated in real-world practice

Lymphoma

Real-World Direct Comparison Shows Superiority of Axi-Cel over Liso-Cel in Patients with R/R LBCL

Lung, Respiratory and Thoracic Cancer

Improved event-free survival after complete or major pathologic response in patients with resectable NSCLC treated with neoadjuvant chemoimmunotherapy regardless of adjuvant treatment: a systematic review and individual patient data meta-analysis

J Thorac Oncol

Marinelli D, Nuccio A, Di Federico A, Ambrosi F, Bertoglio P, Faccioli E, Ferrara R, Ferro A, Giusti R, Guerrera F, Mammana M, Pittaro A, Sepulcri M, Viscardi G, Gallina FT

doi: 10.1016/j.jtho.2024.09.1443

Genitourinary Cancer

PSA Absolute Value Versus PSA Response Rate: Which Is More Valuable for Estimating Survival Outcomes With ARPI Treatment for Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) in Real-World Analyses?

Prostate

Shimomura T, Otsuka N, Urabe F, Muramoto K, Yanagisawa T, Fukuokaya W, Mori K, Tashiro K, Katsumi K, Takahashi H, Yoshihara K, Miyajima K, Imai Y, Iwatani K, Kayano S, Igarashi T, Murakami M, Tsuzuki S, Yamada H, Miki J, Kimura T, JIKEI YAYOI Collaborative Group

doi: 10.1002/pros.24885

ESMO 2024

Genitourinary Cancer

ARANOTE: Adding darolutamide to ADT significantly reduced the risk of radiological progression in patients with mHSPC

SPECIAL REPORT

Genitourinary Cancer

EMBARK: Impact of Enzalutamide Plus ADT on Clinical Practice in Biochemically Recurrent Prostate Cancer

ASH 2024

Lymphoma

Liso-cel is effective and safe in a broad real-world population of R/R LBCL^a patients, including second-line setting and secondary CNS involvement

Lung, Respiratory and Thoracic Cancer

Real-world survival outcomes, treatment patterns, and impact of PD-L1 expression among patients with unresectable, stage III NSCLC treated with CRT → durvalumab in Canada: The RELEVANCE study

Lung Cancer

Wheatley-Price P, Navani V, Pabani A, Routy B, Snow S, Denault MH, Kim Y, Syed I, Devost N, Hui D, Qadeer RA, Arora P, Velummailum R, Springford A, McKibbon C, Ho C

doi: 10.1016/j.lungcan.2025.108583

Leukemia

Cytarabine dose intensification improves survival in older patients with secondary/high-risk acute myeloid leukemia in matched real-world versus clinical trial data

Leuk Lymphoma

Abé C, Keto J, Lilja M, Konradsen M, Mesterton J, Höglund M, Lazarevic V, Lehmann S, Juliusson G

doi: 10.1080/10428194.2024.2363430

ASH 2024

Leukemia

Related content

Real-World Direct Comparison Shows Superiority of Axi-Cel over Liso-Cel in Patients with R/R LBCL

Improved event-free survival after complete or major pathologic response in patients with resectable NSCLC treated with neoadjuvant chemoimmunotherapy regardless of adjuvant treatment: a systematic review and individual patient data meta-analysis

PSA Absolute Value Versus PSA Response Rate: Which Is More Valuable for Estimating Survival Outcomes With ARPI Treatment for Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) in Real-World Analyses?

ARANOTE: Adding darolutamide to ADT significantly reduced the risk of radiological progression in patients with mHSPC

EMBARK: Impact of Enzalutamide Plus ADT on Clinical Practice in Biochemically Recurrent Prostate Cancer

Liso-cel is effective and safe in a broad real-world population of R/R LBCLa patients, including second-line setting and secondary CNS involvement

Real-world survival outcomes, treatment patterns, and impact of PD-L1 expression among patients with unresectable, stage III NSCLC treated with CRT → durvalumab in Canada: The RELEVANCE study

Cytarabine dose intensification improves survival in older patients with secondary/high-risk acute myeloid leukemia in matched real-world versus clinical trial data

Quizartinib shows improved rates of composite complete remission and reduced need for re-induction in real-world patients with FLT3-ITD-mutated AML

Liso-cel is effective and safe in a broad real-world population of R/R LBCL^a patients, including second-line setting and secondary CNS involvement